Plus Therapeutics (PSTV) Stock Price, News & Analysis

Company Overview

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Key Stats

• Today's Range: $1.21 to $1.24
• 50-Day Range: $0.99 to $1.39
• 52-Week Range: $0.93 to $2.67
• Volume: 10,538 shs
• Average Volume: 29,870 shs
• Market Capitalization: $7.31 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.50
• Consensus Rating: Buy

Plus Therapeutics Stock Analysis - MarketRank™

Plus Therapeutics scored higher than 42% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Plus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Plus Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Plus Therapeutics are expected to grow in the coming year, from ($2.30) to ($1.60) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Plus Therapeutics is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Plus Therapeutics is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.97% of the float of Plus Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Plus Therapeutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Plus Therapeutics has recently increased by 20.64%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Plus Therapeutics does not currently pay a dividend.

Dividend Growth

Plus Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.97% of the float of Plus Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Plus Therapeutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Plus Therapeutics has recently increased by 20.64%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Plus Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.49% of the stock of Plus Therapeutics is held by insiders.

Percentage Held by Institutions

Only 3.28% of the stock of Plus Therapeutics is held by institutions.

PSTV Stock Analysis - Frequently Asked Questions

How have PSTV shares performed this year?

Plus Therapeutics' stock was trading at $1.15 at the beginning of 2025. Since then, PSTV stock has increased by 7.8% and is now trading at $1.24.
View the best growth stocks for 2025 here.

How were Plus Therapeutics' earnings last quarter?

Plus Therapeutics, Inc. (NASDAQ:PSTV) announced its quarterly earnings data on Wednesday, May, 15th. The company reported ($0.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.09) by $0.34. The business earned $1.68 million during the quarter.

When did Plus Therapeutics' stock split?

Plus Therapeutics shares reverse split on Monday, May 1st 2023. The 1-15 reverse split was announced on Monday, May 1st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Plus Therapeutics?

Shares of PSTV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Plus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Plus Therapeutics investors own include Meta Platforms (META), CymaBay Therapeutics (CBAY), Advanced Micro Devices (AMD), NVIDIA (NVDA), Arista Networks (ANET), Broadcom (AVGO) and Adobe (ADBE).

Company Calendar

• Last Earnings: 5/15/2024
• Today: 1/21/2025
• Next Earnings (Estimated): 3/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:PSTV
• CUSIP: N/A
• CIK: 1095981
• Web: www.plustherapeutics.com
• Phone: 737-255-7194
• Fax: 858-450-4335
• Employees: 20
• Year Founded: 1996

Price Target and Rating

• Average Stock Price Target: $13.50
• High Stock Price Target: $19.00
• Low Stock Price Target: $8.00
• Potential Upside/Downside: +988.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-13,320,000.00
• Net Margins: -225.07%
• Pretax Margin: -225.07%
• Return on Equity: N/A
• Return on Assets: -154.56%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.44
• Quick Ratio: 0.44

Sales & Book Value

• Annual Sales: $4.91 million
• Price / Sales: 1.49
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.30) per share
• Price / Book: -4.13

Miscellaneous

• Outstanding Shares: 5,896,000
• Free Float: 5,572,000
• Market Cap: $7.31 million
• Optionable: Not Optionable
• Beta: 0.70